Skip to content Skip to footer

News and Insights

News

Vaccines: A Key Weapon Against Antimicrobial Resistance (AMR)

🦠 Vaccines: A Key Weapon Against Antimicrobial Resistance (AMR) A recent WHO report underscores the powerful role of vaccines in the fight against AMR, estimating that better use of vaccines could reduce the global need for antibiotics by 2.5 billion defined daily doses annually—a 22% decrease. This could be a game-changer in reducing the misuse

News

43rd meeting of ISICEM

I enjoy working as CRO and Trial Acceleration company in the highly challenging setting of Intensive Care – as agile, committed smaller companies we can show we make a difference and large CRO fail on the need to be fast and flexible. I attended this 43rd meeting of ISICEM to keep up in sepsis, more

News

News for Gaea Trial Acceleration OÜ

Client 4SC AG:  The Marketing Authorisation Application for resminostat has been accepted by the EMA as sufficient for examination. “Germany, 1 March 2024 – 4SC AG a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), announced today that that its MAA has been accepted by the EMA as sufficient

Leave a request or contact us in any convenient way for you.